Press Room

RDD Europe 2017

Start
Tuesday, April 25, 2017 - 00:00
End
Friday, April 28, 2017 - 00:00
Location: Nice, France
Booth Number: table 35
drug product manufacturing | Hovione

The Respiratory Drug Delivery Europe 2017 will take place in Nice, France and Hovione will be present with a table (nr. 35), a podium presentation, a workshop and a set of posters.

 

HOVIONE PODIUM PRESENTATION

Supercritical-CO2 assisted Spray Drying: Benchmarking Performance, Stability and Scalability of Composite Particles against Conventional Spray Drying
Speaker: Márcio Temtem
Date: Friday, April 28
Time: 10:30 AM

 

HOVIONE WORKSHOP

Advanced Characterization and Design of Inhalable Powder Formulations
Date: Wednesday, April 26
Time: From 2:00 to 6:00 PM

Introduction: Use of advanced analytical characterization tools at all stages of the development of inhaled formulations, from particle engineering to dosing, promotes optimal product design. Combining simple and efficient inhaler design with particle engineering and formulation development can help to achieve the target product profile.

 

HOVIONE POSTERS

Scale-up of a DPI Carrier-based Formulation and Blending Process Optimization by Multivariate Statistical Analysis of a Design of Experiments
Filipa Maia

On the use of Differential Scanning Fluorimetry to Assess the Impact of Spray Drying on Superoxide Dismutase for Dry Powder Inhaler Formulations
Diana Fernandes

Optimization of Formulation and Process Parameters for the Manufacture of Inhalable Composite Particles by Spray-Drying – Effect of Two API Concentration on the In-vitro Aerodynamic Performance
Maria Palha

Paddle over disk as a dissolution test for orally inhaled fluticasone propionate: impact of temperature, dose and formulation
Beatriz Fernandes

 

 

If you are attending RDD Europe and would like to chat with us about your challenges, schedule a meeting with us. Our colleagues will be pleased to meet you.

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026